Performance evaluation of four antibiotics using the BD Phoenix™ NMIC-413 antimicrobial susceptibility testing panel for carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa

The NMIC-413 panel demonstrated Clinical Laboratory Standards Institute (CLSI)-compliant performance for all four tested antibiotics against CRE and CRPA, exhibiting superior reliability compared to the conventional disk diffusion method. Future studies should focus on establishing standardized breakpoints for SCF, expanding the detection spectrum for rare bacterial species, and conducting multicenter validation to assess regional variations. We recommend the NMIC-413 panel for AST of CRE and CRPA isolates as a practical alternative to the BMD method.